GC
MATN

Guggenheim Capital’s Mateon Therapeutics, Inc. MATN Stock Holding History

Guggenheim Capital’s Portfolio MATN Stock Details MATN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-13,948
Closed -$10K – 2956
2016
Q2 		$10K Buy
+13,948
New +$9.88K ﹤0.01% 2848

Other funds holding MATN

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SKK
Shepherd Kaplan Krochuk Boston, Massachusetts $126M AUM 15.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Guggenheim Capital's MATN Position: Q3 2016 in Review

Guggenheim Capital sold out of Mateon Therapeutics, Inc. (MATN) in Q3 2016, closing a stake of 13,948 shares — an estimated $10K sold.

Guggenheim Capital first reported a position in MATN in Q2 2016 and held it in 1 quarter. The position peaked at $10K in Q2 2016. 21 funds tracked by Wall St. Rank hold MATN as of Q3 2016.

  • Guggenheim Capital reported no remaining Mateon Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
  • Guggenheim Capital sold 13,948 Mateon Therapeutics, Inc. shares in Q3 2016, an estimated $10K.
  • Guggenheim Capital first reported a position in Mateon Therapeutics, Inc. in Q2 2016 and held it in 1 quarter.
  • Guggenheim Capital's Mateon Therapeutics, Inc. position peaked at $10K in Q2 2016.
  • 21 funds tracked by Wall St. Rank held Mateon Therapeutics, Inc. as of Q3 2016.

Based on Guggenheim Capital's 13F filing for Q3 2016, filed 15 Nov 2016.